Evidence map›Paper›PMID 33219298›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2021

Next-Generation Scholarship: Rebranding Hematopathology Using Twitter: The MD Anderson Experience.

Siba El Hussein, Joseph D Khoury, Kirill A Lyapichev, Mehrnoosh Tashakori, Mahsa Khanlari, Roberto N Miranda, Rashmi Kanagal-Shamanna, Sa A Wang, Aadil Ahmed, Kamran M Mirza and 3 more

Abstract readEditorial
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Siba El HusseinDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. elhusseinsiba@gmail.com.
Joseph D KhouryDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kirill A LyapichevDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mehrnoosh TashakoriDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mahsa KhanlariDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Roberto N MirandaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rashmi Kanagal-ShamannaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-7829-5249
Sa A WangDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Aadil AhmedDepartment of Pathology and Laboratory Medicine, The University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Kamran M MirzaDepartment of Pathology and Laboratory Medicine, Loyola University Health System, Maywood, IL, USA.
Genevieve M CraneRobert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.
L Jeffrey MedeirosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-6577-8006
Sanam LoghaviDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Sloghavi@mdanderson.org.ORCID http://orcid.org/0000-0001-8980-3202

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematopathologists are witnessing very exciting times, as a new era of unsurpassed technological advances is unfolding exponentially, enhancing our understanding of diseases at the genomic and molecular levels. In the evolving field of precision medicine, our contributions as hematopathologists to medical practice are of paramount importance. Social media platforms such as Twitter have helped facilitate and enrich our professional  interactions and collaborations with others in our field and in other medical disciplines leading to a more holistic approach to patient care. These platforms also have created a novel means for instantaneous dissemination of new findings and recent publications, and are proving to be increasingly useful tools that can be harnessed to expand our knowledge and amplify our presence in the medical community. In this Editorial, we share our experience as hematopathologists with Twitter, and how we leveraged this platform to boost scholarly activities within and beyond our subspecialty, and as a powerful medium for worldwide dissemination of educational material and to promote our remote teaching activities during the COVID-19 pandemic.

Indexed as

COVID-19Education, Medical, ContinuingScholarly CommunicationSocial MediaCongresses as TopicHematologyHumansInformation DisseminationPathologistsPathologySpecializationTexasVideoconferencing

Identifiers

PMID33219298
PMCPMC7678590

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.